Versatile fluorescence biosensors based on CRISPR/Cas12a for determination of site-specific DNA methylation from blood and tissues
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · 2025-03 · 329 · 125520
DOI: 10.1016/j.saa.2024.125520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2025-03. Verfasst von Lihua Ding und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Public Health, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: DNA Methylation, Biosensing Techniques, CRISPR-Cas Systems, Endodeoxyribonucleases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
The identification of DNA methylation at specific sites is crucial for the early detection of cancer since DNA methylation is intimately associated to the occurrence and development of cancer. Herein, two types of sensors that can detect site-specific DNA methylation were developed to meet practical requirements using methylation sensitive restriction endonuclease and CRISPR/Cas12a. To accomplish rapid detection of target, an AciI-mediated CRISPR/Cas12a assay was developed by coupling AciI to recognize DNA methylation with Cas12a to identify site-specific DNA. Since protospacer adjacent motif (PAM)-dependent endonuclease activity and trans-cleavage activity of Cas12a, it is possible to detect site-specific DNA methylation within 2 h with high specificity and acceptable sensitivity. To satisfy the needs of trace target detection, we developed an GlaI-strand displacement amplification (SDA) assisted CRISPR/Cas12a system. The system converts double-stranded methylated DNA to abundant single-stranded by GlaI and SDA. Then, the combination of SDA and CRISPR/Cas12a enable cascades amplification of signal. The approach can therefore be used to detect methylation at different specified sites, even those without PAM, and can increase sensitivity with a detection limit down to 8.19 fM. Importantly, the assay can distinguish between colorectal cancer and precancerous tissue, as well as identify colorectal patients and healthy people. This study provides a new avenue for the development of new biosensors for methylation analysis, and the two methods devised have the potential to meet the multiple requirements of site-specific methylation testing in various clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
- College of Public Health, Zhengzhou University, Zhengzhou 450001, China; School of Nursing and Health, Zhengzhou University, Zhengzhou, China. Electronic address: scyu@zzu.edu.cn.
Zitieren
APA
Ding, L., Cao, S., Bai, L., He, S., He, L., Wang, Y., Wu, Y., & Yu, S. (2025). Versatile fluorescence biosensors based on CRISPR/Cas12a for determination of site-specific DNA methylation from blood and tissues. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 329, 125520. https://doi.org/10.1016/j.saa.2024.125520
Vancouver
Ding L, Cao S, Bai L, He S, He L, Wang Y, et al. Versatile fluorescence biosensors based on CRISPR/Cas12a for determination of site-specific DNA methylation from blood and tissues. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2025;329:125520. doi:10.1016/j.saa.2024.125520
BibTeX
@article{Ding2025,
author = {Ding, Lihua and Cao, Shengnan and Bai, Lanxin and He, Sitian and He, Leiliang and Wang, Yilin and Wu, Yongjun and Yu, Songcheng},
title = {Versatile fluorescence biosensors based on CRISPR/Cas12a for determination of site-specific DNA methylation from blood and tissues},
journal = {Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy},
year = {2025},
volume = {329},
pages = {125520},
doi = {10.1016/j.saa.2024.125520}
}
EUVIMED